Shots:

• Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab- IV- 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia in Japan
• The company will start enrolling once the details of the diseases get finalized. Earlier- Roche has initiated P-III COVACTA study assessing Actemra + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia across the globe including the US- Canada and EU
• Actemra is a humanized anti-human IL-6 receptor mAb and has received the US FDA’s approval for RA in 2010 and was launched in Jun’2005 for multiple indications in Japan

Click here ­to­ read full press release/ article | Ref: Roche | Image: Chugai